The following article appeared online today on InsideHealthPolicy.com, a subscription service. We are sharing the full article here.
Posted: May 16, 2013
Rare Disease Group Pushes Endpoint Discussion In FDASIA Guide
Without key changes to FDA's consideration of surrogate and intermediate endpoints, drugs in the pipeline to treat muscular dystrophy will not make it to…Continue